How Much Is Amarin Really Worth?
Amarin (NASDAQ: AMRN) is about to make a boatload of money. Probably no one familiar with the biotech would argue that point.
In December, the FDA gave the go-ahead to a new label expansion for Amarin's sole approved drug, Vascepa, in reducing cardiovascular risk. While Vascepa has been on the market for around seven years as a treatment for lowering triglyceride levels, the latest FDA approval opens the door for the drug to be prescribed for many more patients.
But just how much is Amarin worth now that it has what many consider to be a surefire blockbuster on its hands? Here are answers to that important question as examined from three different angles.
Source Fool.com
